8% OTSUKA amino acid intravenous injection solution for liver brain disease in patients with chronic liver failure (200ml)

Dosage form Bottle x 200ml
Specifications L-Arginine HCl, L-Histidine, L-Methionine, L-Phenylalanine, L-Threonine, L-Valine, Glycine, L-Lysine, L-TRYPTOPHAN, L-LEUCINE, L-Isoleucine, L-Proline, L-Serine, L-Alanine, L-Cysteine, Sodium Bisulfite
Ingredient OTSUKA Vietnam Pharmaceutical Joint Stock Company

Ingredient

Thành phần cho 200ml

Composition information	Content
L-Arginine HCl	1.46g
L-histidine	0.64g
L-Methionine	0.2g
L-phenylalanine	0.2g
L-Threonine	0.9g
L-Valine	1.68g
Glycine	1.8g
L-lysine	1.52g
L-tryptophan	0.14g
L-leucine	2.2g
L-ISOLEUCINE	1.8g
L-Proline	1.6g
L-Serine	1g
L-alanine	1.5g
L-Cysteine	0.08g
Sodium Bisulfite	0.06g

Uses

Indications

Treatment of liver brain disease in patients with chronic liver failure.

Pharmacokinus

When infusion of aminoleban veins for patients with chronic liver brain brain, quickly improve coma (index assessment of consciousness) and rapid reduction of ammonia in the blood.

Aminoleban improves mental function, is assessed by writing, drawing, tremor, digital connection test, orientation and calculation as well as the results of the brain.

The effect of Aminoleban on liver brain disease in clinical studies summarized in the table below:

Clinical circumstances improvement rate* (56/90)

brain disease due to other causes 62.5% (August 5)

love.

Dynamic pharmacokinetics

Amino acids marked with carbon on the formula of aminoleban are easily distributed in the body after intravenous transmission to mice. After 6 hours, 50 - 70% of amino acids are distributed in plasma protein segments, the ratio of branch amino acids compared to total amino acids is the highest in the brain. Within 72 hours after the transmission, the elimination of the drug was 5.9% in the urine, 2.6% in feces and 41.7% in exhaled gas.

Before taking 8% OTSUKA amino acid intravenous injection solution for liver brain disease in patients with chronic liver failure (200ml)

How to use

Intravenous infusion.

Dosage

The usual dose in adults is 500 ml - 1000 ml of aminoleban solution for an infusion by transmitting drip.

Average transmission speed through peripheral venous system is 1.7 - 2.7 ml/min in adults (equivalent to 3-5 hours for 500 ml).

The total dose used for nutrition on the gastrointestinal tract is 500 ml - 1000 ml of solution.

Aminoleban combined with a Dextrose solution or another compounding solution transmitted within 24 hours via the central vein system.

The dose is also adjusted depending on the age, symptoms and weight of the patient. Used in older people: Older patients often have decline in physiological functions, so to be cautious, they should reduce the dose and speed of transmission.What to do when overdose?

If there is an overdose, it is advisable to re -evaluate the patient condition and apply appropriate treatments.

Side Effects

Hypersensitivity reactions: rarely encounter skin rash. If the skin rash occurs, it is necessary to stop the infusion and take appropriate treatments.

Gastrointestinal tract: occasionally vomiting and nausea.

Cardiovascular system: rarely chest pain and chest drum.

Metabolism: The amount of nitrogen in this preparation may temporarily cause increased blood ammonia concentration in the blood.

When transmitting a large amount of Aminoleban solution or transmitting at a fast speed may occur in acidosis.

Other effects: rarely occurs chilling, fever, headache, vascular pain.

Notify the doctor with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Severe kidney failure

Abnormality of amino acid metabolism due to other liver causes.

Severe heart failure.

Disorders of water metabolism and electrolytes.

Be cautious when using

be cautious when using aminoleban in the following cases:

Patients with severe acidosis.

Patients with congested heart failure.

Patients with severe and severe dehydration.

Note when using:

Before using:

To avoid cross -bacterial infections, appropriate sterilization measures (sterilization of infusion and infusion skin area).

While using:

Slow transmission through peripheral intravenous system.

Other notes:

Before opening the nylon bag, you need to check the color of the color indicator, do not use the bottle if the color indicator has turned blue or purple. Label.

Used in older adults:

Older patients often have a decrease in physiological functions, so to be cautious should reduce the dose and transmission speed.

The effect of the drug on driving and operating machinery

No report.

Use drugs for women during pregnancy and lactation

Be careful when used for pregnant women.

Drug interaction

Tuong:

The physical and chemical properties of the drug solution may change (precipitate may appear) when combining aminoleban with the following drugs:

Sustainable drugs in alkaline environment.

Water -soluble drugs.

If these signs appear not to use drug solutions.

To minimize the risk of a drug taboo when transmitting this drug with other drugs, check the turbidity and precipitate of the solution immediately after mixing the drug, before transmitting and checking periodically during the infusion process.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

To be out of reach of children, read the user manual carefully before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.